PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders First...
PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders First...
Amphista Therapeutics has unveiled new data demonstrating the potential of its protein degraders in animal models, a step toward bringing the tech to the clinic.
PRESS RELEASE Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb Cambridge, UK, September 26th, 2023 “ Amphista Therapeutics (œthe Company or...
CAMBRIDGE, England, May 4, 2023 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the delivery of the first discovery milestone under its collaboration and license agreement with Bristol Myers Squibb, triggering a payment for achieving the milestone.
CAMBRIDGE, England, May 2, 2023 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD), today announced that Louise Modis, PhD, has joined the company as Chief Scientific Officer (CSO) and Ian Churcher, DPhil, will transition to the role of Chief Technology Officer (CTO).
CAMBRIDGE, England, Dec. 13, 2022 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced a Series B extension investment by the Dementia Discovery Fund (DDF). The investment is in recognition of the progress made in relation to Amphista's Eclipsys™ platform and its potential to enable therapies to treat diseases of the central nervous system, with a focus on neurodegeneration.
Amphista – a company involved in the development of next generation targeted protein degradation (TPD) therapeutics – has linked up with Domainex in an integrated drug discovery partnership.
Amphista Therapeutics has forged two significant protein degradation partnerships with big pharma. On Wednesday, the U.K.-based company announced partnerships with both Bristol Myers Squibb and Merck KGaA that have a combined value of more than $2 billion.
GLASGOW, Scotland, Sept. 21, 2021 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Joshua T. Brumm as its new Independent Chairman, succeeding Satish Jindal.